1. Unlikely to survive after 48 hours from screening or unlikely to remain at the investigational site beyond 48 hours <br/ > 2. Requiring organ support at screening (Organ support defined as need for ICU care, mechanical ventilation, Non Invasive Ventilation (NIV), High flow Nasal Oxygen at screening <br/ > 3. Participation in any other clinical trial of an experimental treatment for COVID-19 <br/ > 4. Known hypersensitivity to the trial drug or its components <br/ > 5. Pregnant women or women who are breastfeeding <br/ > 6. Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive study treatment <br/ > 7. Unable to provide consent <br/ >

1. Unlikely to survive after 48 hours from screening or unlikely to remain at the investigational site beyond 48 hours <br/ > 2. Requiring organ support at screening (Organ support defined as need for ICU care, mechanical ventilation, Non Invasive Ventilation (NIV), High flow Nasal Oxygen at screening <br/ > 3. Participation in any other clinical trial of an experimental treatment for COVID-19 <br/ > 4. Known hypersensitivity to the trial drug or its components <br/ > 5. Pregnant women or women who are breastfeeding <br/ > 6. Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive study treatment <br/ > 7. Unable to provide consent <br/ >